NEW YORK (GenomeWeb News) – Meridian Bioscience said on Monday that its illumigene Group A Streptococcus and illumigene Group B Streptococcus assays have been recategorized by the US Food and Drug Administration as "moderate complexity" tests under the Clinical Laboratory Improvement Amendments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.